Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Bowel Perforation After Treatment with Sorafenib: A Case Report and Review of Literature.

× No keyword cloud information.

15 in total

1. Bowel perforation after radiotherapy in a patient receiving sorafenib.

Authors: Natascha A J B Peters; Dick J Richel; Joost J C Verhoeff; Lukas J A Stalpers
Journal: J Clin Oncol Date: 2008-05-10 Impact factor: 44.544

2. Antiangiogenic agents for the treatment of nonsmall cell lung cancer: characterizing the molecular basis for serious adverse events.

Authors: Shenhong Wu; Roger S Keresztes
Journal: Cancer Invest Date: 2011-08 Impact factor: 2.176

3. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas.

Authors: Robert G Maki; David R D'Adamo; Mary L Keohan; Michael Saulle; Scott M Schuetze; Samir D Undevia; Michael B Livingston; Matthew M Cooney; Martee L Hensley; Monica M Mita; Chris H Takimoto; Andrew S Kraft; Anthony D Elias; Bruce Brockstein; Nathalie E Blachère; Mark A Edgar; Lawrence H Schwartz; Li-Xuan Qin; Cristina R Antonescu; Gary K Schwartz
Journal: J Clin Oncol Date: 2009-05-18 Impact factor: 44.544

4. Sorafenib and surgical complications: a case report of adverse reaction to sorafenib during treatment for renal cell carcinoma.

Authors: F C S Eng; A M Easson; E Szentgyorgyi; J J Knox
Journal: Eur J Surg Oncol Date: 2007-11-05 Impact factor: 4.424

5. Increased bowel toxicity in patients treated with a vascular endothelial growth factor inhibitor (VEGFI) after stereotactic body radiation therapy (SBRT).

Authors: Brandon M Barney; Svetomir N Markovic; Nadia N Laack; Robert C Miller; Jann N Sarkaria; O Kenneth Macdonald; Heather J Bauer; Kenneth R Olivier
Journal: Int J Radiat Oncol Biol Phys Date: 2013-09-01 Impact factor: 7.038

Review 6. Risk of gastrointestinal perforation in cancer patients treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis.

Authors: Wei-Xiang Qi; Yuan-Jue Sun; Li-Na Tang; Zan Shen; Yang Yao
Journal: Crit Rev Oncol Hematol Date: 2013-10-12 Impact factor: 6.312

Review 7. Angiogenesis: a promising therapeutic target for ovarian cancer.

Authors: A Bamias; S Pignata; E Pujade-Lauraine
Journal: Crit Rev Oncol Hematol Date: 2012-05-08 Impact factor: 6.312

8. Colon perforation during sorafenib therapy for advanced hepatocelluar carcinoma. A case report.

Authors: Sang-Gon Park; Choon-Hae Chung; Chi-Young Park
Journal: Tumori Date: 2011 Nov-Dec

9. A phase II trial of sorafenib in metastatic melanoma with tissue correlates.

Authors: Patrick A Ott; Anne Hamilton; Christina Min; Sara Safarzadeh-Amiri; Lauren Goldberg; Joanne Yoon; Herman Yee; Michael Buckley; Paul J Christos; John J Wright; David Polsky; Iman Osman; Leonard Liebes; Anna C Pavlick
Journal: PLoS One Date: 2010-12-29 Impact factor: 3.240

Review 10. Antiangiogenic tyrosine kinase inhibition related gastrointestinal perforations: a case report and literature review.

Authors: Maudy Walraven; Petronella O Witteveen; Martijn P J Lolkema; R van Hillegersberg; Emile E Voest; H M W Verheul
Journal: Angiogenesis Date: 2010-12-29 Impact factor: 9.596